What question did this study set out to answer?

The aim is to enhance healthcare providers' confidence and skills in managing early-stage type 1 diabetes through a structured training program.

June 7, 2026

2227-P: Ask the Experts Mini Fellowship: Preventing the Crisis

Key Points

The aim is to enhance healthcare providers' confidence and skills in managing early-stage type 1 diabetes through a structured training program.
Pilot of a 1-day CME-accredited mini-fellowship including didactic and case-based learning.
Evaluation employed the Kirkpatrick-Barr framework at three time points: pre-course, end of day, and 60 days post-course.
Involved case-based Zoom sessions for six months following the initial training.
Self-efficacy scores increased from 4.23 to 4.95 on a 1-5 Likert scale (+0.72 points).
100% of attendees recommended the program to colleagues, indicating perceived value.
Respondents reported that screening for autoantibodies and follow-up reduced the risk of diabetic ketoacidosis.

Abstract

Introduction and Objective: Ask the Experts (EXPERTS) supports U.S. individuals who screen positive for type 1 diabetes islet autoantibodies (IA) and their health care providers (HCPs). Because clinical capacity to monitor and counsel patients with early-stage type 1 diabetes remains limited, we piloted a 1-day CME-accredited mini-fellowship to build HCP confidence and capacity for early-stage type 1 diabetes follow-up. Here we describe the program and report initial evaluation findings. Methods: The in-person course combined didactics with interactive, case-based learning led by multidisciplinary faculty, plus six-monthly case-based Zoom sessions. Evaluation used the Kirkpatrick-Barr framework at pre-course (T0), end of day (T1), and 60 days (T2), assessing case-based knowledge, attitudes, self-efficacy, satisfaction/recommendation, and commitment-to-change with a brief T2 implementation snapshot. Results: Thirteen HCPs attended (4 MD, 1 DO, 2 PA-C, 1 MSN, 2 BSN, 3 RD/CDCES) from 9 states (CA, CO, IA, MI, NC, NJ, TN, TX, VA). End-of-day feedback reflected high perceived value and intent to apply course content. Mean self-efficacy increased from 4.23 (T0) to 4.95 (T1) on a 1-5 Likert scale (+0.72 points), and 100% would recommend the program to a colleague. At 60 days, respondents reported completing clinical practice action items, identifying barriers, and using EXPERTS web-based guides/tools to support decision-making. Respondents reported IA screening and follow-up reduces diabetic ketoacidosis risk and clinics should adopt an IA-based triage workflow when feasible. Conclusion: A brief, CME-accredited training with longitudinal case-based support and pragmatic evaluation may help expand national capacity for early-stage type 1 diabetes screening and follow-up. Disclosure K. Bautista: None. R.K. deRijk: None. M. Munoz: None. T. Fleury: None. I. Taki: None. H. O'Donnell: Consultant; Current; Sanofi. Advisory Panel; Ended; Sanofi. Stock/Shareholder; Current; Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc. D. Felipe-Morales: None. K. Simmons: None. Funding Helmsley Charitable Trust Grant project reference number R-2409-07365. Unique project number is 25B5320

Mark Helpful

Bookmark

Relay